Eine Erst-in-Human-Studie über KK2223 bei Teilnehmern mit rezidiviertem oder refraktärem T-Zell-Nicht-Hodgkin-Lymphom
Eine Phase 1, eine multizentrische, offene Label, nicht randomisierte, dosis-Eskalation und Backfüllung von KK2223 bei Teilnehmern mit rezidiviertem oder refraktärem T-Zell-Nicht-Hodgkin-Lymphom
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Kyowa Kirin, Inc.
- Telefonnummer: +1-609-919-1100
- E-Mail: KKD.Clinical.82@kyowakirin.com
Studienorte
-
-
-
Bergamo, Italien, 24127
- Noch keine Rekrutierung
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
-
Hauptermittler:
- Giuseppe Gritti
-
Kontakt:
- Giuseppe Gritti
- Telefonnummer: 39035269492
- E-Mail: giuseppe_gritti@yahoo.it
-
Bologna, Italien, 40138
- Noch keine Rekrutierung
- Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
-
Kontakt:
- Luigi Zinzani Pier
- Telefonnummer: 390516363680
- E-Mail: pierluigi.zinzani@unibo.it
-
Hauptermittler:
- Luigi Zinzani Pier
-
Torino, Italien, 10126
- Noch keine Rekrutierung
- AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
-
Kontakt:
- Federica Cavallo
- Telefonnummer: 390116334264
- E-Mail: f.cavallo@unito.it
-
Hauptermittler:
- Federica Cavallo
-
-
Torino
-
Candiolo, Torino, Italien, 10060
- Noch keine Rekrutierung
- Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
-
Hauptermittler:
- Umberto Vitolo
-
Kontakt:
- Umberto Vitolo
- Telefonnummer: 390116335934
- E-Mail: umberto.vitolo@ircc.it
-
-
-
-
-
Madrid, Spanien, 28027
- Noch keine Rekrutierung
- Clinica Universidad de Navarra - Hematología y Hemoterapia
-
Kontakt:
- Miguel Canales Albendea
- Telefonnummer: 34917277116
- E-Mail: macanales@unav.es
-
Hauptermittler:
- Migue Canales Albendea
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 8036
- Noch keine Rekrutierung
- Hospital Clinic De Barcelona - Hematología
-
Hauptermittler:
- Pablo Mozas
-
Kontakt:
- Pablo Mozas
- Telefonnummer: 34 93 227 22 71
- E-Mail: mozas@clinic.cat
-
L'Hospitalet de Llobregat, Barcelona, Spanien, 8907
- Noch keine Rekrutierung
- Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
-
Hauptermittler:
- Eva Domingo Domenech
-
Kontakt:
- Eva Domingo Domenech
- Telefonnummer: 34932607822
- E-Mail: edomingo@iconcologia.net
-
-
Navarre
-
Pamplona, Navarre, Spanien, 31008
- Noch keine Rekrutierung
- Clinica Universidad de Navarra - Hematología
-
Kontakt:
- Miguel Canales Albendea
- Telefonnummer: 34917277116
- E-Mail: macanales@unav.es
-
Hauptermittler:
- Miguel Canales Albendea
-
-
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- Noch keine Rekrutierung
- City of Hope
-
Hauptermittler:
- Christina Poh
-
Kontakt:
- Christina Poh
- Telefonnummer: 916-734-7131
- E-Mail: cpoh@coh.org
-
Orange, California, Vereinigte Staaten, 92868
- Noch keine Rekrutierung
- University of California, Irvine Medical Center - Hematology/Oncology
-
Kontakt:
- Lauren Pinter Brown
- Telefonnummer: 7144568200
- E-Mail: lpinterb@uci.edu
-
Hauptermittler:
- Lauren Pinter Brown
-
Stanford, California, Vereinigte Staaten, 94305
- Rekrutierung
- Stanford University School of Medicine
-
Hauptermittler:
- Youn Kim
-
Kontakt:
- Youn Kim
- Telefonnummer: 650-723-7893
- E-Mail: younkim@stanford.edu
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- Noch keine Rekrutierung
- Moffit Cancer Center
-
Kontakt:
- Yumeng Zhang
- Telefonnummer: 844-304-8636
- E-Mail: yumeng.zhang@moffitt.org
-
Hauptermittler:
- Yumeng Zhang
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Noch keine Rekrutierung
- Emory University Medical Center
-
Hauptermittler:
- Pamela Allen
-
Kontakt:
- Pamela Allen
- Telefonnummer: 404-778-2407
- E-Mail: pallen5@emory.edu
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Noch keine Rekrutierung
- University of Iowa Health
-
Hauptermittler:
- Eric Mou
-
Kontakt:
- Eric Mou
- Telefonnummer: 800-777-8442
- E-Mail: eric-mou@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Noch keine Rekrutierung
- Beth Israel Deaconess Medical Center - Research
-
Kontakt:
- Salvia Jain
- Telefonnummer: 617-726-2000
- E-Mail: salvia.jain@mgh.harvard.edu
-
Hauptermittler:
- Salvia Jain
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine - Oncology Hospital - Public
-
Hauptermittler:
- Neha Mehta Shah
-
Kontakt:
- Neha Mehta Shah
- Telefonnummer: 314.273-8566
- E-Mail: mehta-n@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601-2105
- Noch keine Rekrutierung
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
-
Hauptermittler:
- Tatyana Feldman
-
Kontakt:
- Tatyana Feldman
- Telefonnummer: 551-996-5900
- E-Mail: tatyana.feldman@hmhn.org
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021-6007
- Rekrutierung
- Memorial Sloan Kettering Cancer Center
-
Hauptermittler:
- Jasmine Zain
-
Kontakt:
- Jasmine Zain
- Telefonnummer: 212-639-3045
- E-Mail: zainj1@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Noch keine Rekrutierung
- University Hospitals Cleveland Medical Center
-
Kontakt:
- Kevin Cooper
- Telefonnummer: 216-844-8200
- E-Mail: kevin.cooper@uhhospitals.org
-
Hauptermittler:
- Kevin Cooper
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Noch keine Rekrutierung
- Oregon Health & Science University
-
Kontakt:
- Craig Okada
- Telefonnummer: 503-494-8397
- E-Mail: okadac@ohsu.edu
-
Hauptermittler:
- Craig Okada
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Noch keine Rekrutierung
- University of Pennsylvania - Abramson Cancer Center
-
Hauptermittler:
- Stefan Barta
-
Kontakt:
- Stefan Barta
- Telefonnummer: 215-728-2674
- E-Mail: Stefan.Barta@pennmedicine.upenn.edu
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- The University of Texas - MD Anderson Cancer Center
-
Hauptermittler:
- Ranjit Nair
-
Kontakt:
- Ranjit Nair
- Telefonnummer: 171-379-2860
- E-Mail: rnair@mdanderson.org
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
- PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
- Availability of tumor tissue (current or archival) is required.
- Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
- ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
- Body weight 40 kg to ≤ 200 kg
- Life expectancy ≥3 months.
- Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
- Restrictions on gamete donation and freezing during and after treatment.
- Ability to provide informed consent and comply with study procedures. -
Exclusion Criteria:
- Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
- Pregnant or breastfeeding females, or those intending pregnancy.
- History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
- Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
- Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
- Use of other investigational drugs within 14 days or 5 half-lives before treatment.
- Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
- Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
- Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
- Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
- Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
- Prolonged QT/QTc interval (e.g., QTcF >480 ms).
- Active second primary malignancies except specified non-exclusionary cases.
- CNS involvement.
- Any condition that may impair compliance or study completion as judged by the Investigator.
- Known hypersensitivity to any excipients in the drug formulation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Part One (Dose Escalation)
In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design. |
Intravenous infusion |
|
Experimental: Part Two (Backfill)
Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment. |
Intravenous infusion |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Zeitfenster: Through study completion, an average of 1.5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Zeitfenster: Through study completion, an average of 1.5 years
|
Vital signs (mmHg in Systolic/Diastolic blood pressure) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Zeitfenster: Through study completion, an average of 1.5 years
|
Pulse rate (beats/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Zeitfenster: Through study completion, an average of 1.5 years
|
Respiratory Rate (breath/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Zeitfenster: Through study completion, an average of 1.5 years
|
Temperature (°Celcius) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Zeitfenster: Through study completion, an average of 1.5 years
|
ECG parameters (PR interval, QRS interval, QT interval, QTc interval) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Zeitfenster: Through study completion, an average of 1.5 years
|
Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD) |
Through study completion, an average of 1.5 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mean Blood Drug Concentration
Zeitfenster: Through study completion, an average of 1.5 years
|
The mean drug concentration in the blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the immunogenicity of KK2223.
Zeitfenster: Through study completion, an average of 1.5 years
|
Incidence of Anti drug antibodies (ADA) in blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Zeitfenster: Through study completion, an average of 1.5 years
|
% in Overall Response Rate (ORR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Zeitfenster: Through study completion, an average of 1.5 years
|
% in Compartment Response (if applicable) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Zeitfenster: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Duration of Response (DOR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Zeitfenster: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Zeitfenster: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Response (TTR) |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Zeitfenster: Through study completion, an average of 1.5 years
|
The maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Zeitfenster: Through study completion, an average of 1.5 years
|
A measure of the overall drug exposure over time |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Zeitfenster: Through study completion, an average of 1.5 years
|
The time taken to reach the maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Zeitfenster: Through study completion, an average of 1.5 years
|
The time required for the drug concentration to decrease by 50% |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Clearance (CL)
Zeitfenster: Through study completion, an average of 1.5 years
|
Rate of drug elimination from the body |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Zeitfenster: Through study completion, an average of 1.5 years
|
Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues |
Through study completion, an average of 1.5 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom, Non-Hodgkin
- Lymphom, T-Zell
- Hämische und lymphatische Krankheiten
- Neubildungen
- Lymphom
- Lymphom, T-Zelle, peripher
- Lymphom, T-Zelle, Haut
- Erkrankungen des Immunsystems
- Mycosis fungoides
- Sezary-Syndrom
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2223-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .